Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Velabs Therapeutics, a Germany-based biotechnology spinout of European Molecular Biology Laboratory (EMBL), secured €3m ($3.5m) in series B funding yesterday from undisclosed backers. The spinout uses microfluidic technology to test millions of antibodies for their therapeutics effects, working both in partnership with pharmaceutical firms and building its own pipeline of assets. Velabs will use the…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.